BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 02, 2006
 |  BioCentury  |  Product Development

NovaCardia's kidney sparing diuretic

In heart failure patients, loss of kidney function is a good predictor of longer hospital stays and mortality. Marketed heart failure medications - diuretics and vasodilators - often cause renal damage, thereby complicating their use and, in severe cases, confounding their therapeutic benefit. NovaCardia Inc. believes that its KW-3902 diuretic will protect or even improve renal function. In addition, given its mechanism, it should be synergistic with marketed diuretics.

This week, NovaCardia (San Diego, Calif.) was to report data from three U.S. Phase II trials (CKI-201, CKI-202 and CKI-203) showing the ability of the adenosine A1 receptor antagonist to increase urine volume while preserving or improving renal function in heart failure patients. The company plans to start Phase III testing in the second quarter, once it has closed a planned $55 million series B round, according to Howard Dittrich, senior vice president of clinical research and regulatory affairs(see B16).

CKI-201 enrolled 146 patients with mild to moderate renal impairment (defined as creatinine clearance of 20-80 mL/min) who required hospitalization for intravenous diuretic treatment of acute exacerbation of...

Read the full 882 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >